Cellectar Says Iopofosine I 131 Showed 87.5% Response Rate In 24-Patient Post-BTK Inhibitor Subgroup Of Phase 2b Waldenström Macroglobulinemia Trial
Share
Why It Matters
Cellectar tested a cancer medicine on 24 patients with a rare blood disease. Most patients responded well, which shows the medicine might help people whose other treatments stopped working.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.